<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title> &#187; Understanding the Global Pharmaceutical Market</title>
	<atom:link href="http://pharmaexecnews.com/tag/understanding-the-global-pharmaceutical-market/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaexecnews.com</link>
	<description></description>
	<lastBuildDate>Fri, 29 Apr 2011 14:00:12 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Zymes Receives Michael Fox Foundation Grant for PD Therapy Research</title>
		<link>http://pharmaexecnews.com/biotechnology/zymes-receives-michael-fox-foundation-grant-pd-therapy-research/</link>
		<comments>http://pharmaexecnews.com/biotechnology/zymes-receives-michael-fox-foundation-grant-pd-therapy-research/#comments</comments>
		<pubDate>Tue, 01 Mar 2011 14:00:17 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11237</guid>
		<description><![CDATA[Zymes, a New Jersey-based biopharmaceutical company, has received a two-year $476,000 grant from the Michael J Fox Foundation (MJFF), under the Therapeutics Development Initiative Fall 2010 Program, to evaluate the effectiveness of WS-CoQ10 in stopping the progressive loss of dopamine nerve cells in animal models of Parkinson&#8217;s disease (PD).

Zymes is engaged in developing a novel, [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/zymes-receives-michael-fox-foundation-grant-pd-therapy-research/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Pneumococcal Vaccine Developed</title>
		<link>http://pharmaexecnews.com/biotechnology/pneumococcal-vaccine-developed/</link>
		<comments>http://pharmaexecnews.com/biotechnology/pneumococcal-vaccine-developed/#comments</comments>
		<pubDate>Tue, 01 Mar 2011 08:00:41 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11205</guid>
		<description><![CDATA[Nearly eleven percent of mortality in young children globally is the result of Pneumococcus (Streptococcus pneumoniae). While there are many vaccines that combat this disease successfully (Prevnar being one of the most famous ones), they are quite expensive and usually target only specific strains of the virus.

Now, Genocea Biosciences Inc, Boston Children’s Hospital, and a [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/pneumococcal-vaccine-developed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MedTrust, Avantra Partner to Develop Biomarker Assays for Cancer</title>
		<link>http://pharmaexecnews.com/biotechnology/medtrust-avantra-partner-develop-biomarker-assays-cancer/</link>
		<comments>http://pharmaexecnews.com/biotechnology/medtrust-avantra-partner-develop-biomarker-assays-cancer/#comments</comments>
		<pubDate>Mon, 28 Feb 2011 14:00:33 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[biochip]]></category>
		<category><![CDATA[biochips]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[c reactive protein]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11234</guid>
		<description><![CDATA[MedTrust Online and Avantra Biosciences have entered into a partnership to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences&#8217; revolutionary QPDx multiplex immunoassay system.

The two companies will provide over 10,000 cancer care professionals with early access to the latest panels of protein biomarkers implicated in different cancers.
Avantra had announced [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/medtrust-avantra-partner-develop-biomarker-assays-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Top 10 Medical Device Venture Capital Deals of 2010</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/top-10-medical-device-venture-capital-deals-2010/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/top-10-medical-device-venture-capital-deals-2010/#comments</comments>
		<pubDate>Mon, 28 Feb 2011 08:00:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Devices and Technology]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11201</guid>
		<description><![CDATA[Fierce Medical Device&#8217;s first annual look at the top 10 VC deals of the year. Venture capital investment in the medical device industry fell 9 percent in 2010, ending the year as the fourth largest investment sector with $2.3 billion going into 324 deals. That&#8217;s up slightly over 2009, when medical devices ranked third among [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/top-10-medical-device-venture-capital-deals-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OTC Allegra Nod Fortifies Sanofi&#8217;s U.S. Consumer Ops</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/otc-allegra-nod-fortifies-sanofis-consumer-ops/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/otc-allegra-nod-fortifies-sanofis-consumer-ops/#comments</comments>
		<pubDate>Fri, 25 Feb 2011 14:00:39 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Companies]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11219</guid>
		<description><![CDATA[Sanofi-Aventis continues its diversification march. The company got the FDA&#8217;s permission to sell its blockbuster allergy treatment Allegra without a prescription. Sanofi has been hoping for that OK to bolster its U.S. consumer healthcare business that was created last year with the $1.9 billion purchase of Chattem.

At the time, both companies trumpeted OTC Allegra&#8217;s potential [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/otc-allegra-nod-fortifies-sanofis-consumer-ops/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Inhalable Measles Vaccine Tested</title>
		<link>http://pharmaexecnews.com/biotechnology/inhalable-measles-vaccine-tested/</link>
		<comments>http://pharmaexecnews.com/biotechnology/inhalable-measles-vaccine-tested/#comments</comments>
		<pubDate>Fri, 25 Feb 2011 08:00:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11197</guid>
		<description><![CDATA[Sustained high vaccination coverage is key to preventing deaths from measles. Despite the availability of a vaccine, measles remains an important killer of children worldwide, particularly in less-developed regions where vaccination coverage is limited. A team of researchers, led by scientists at the Johns Hopkins Bloomberg School of Public Health and the University of Colorado, [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/inhalable-measles-vaccine-tested/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Naturally Occurring Brain Signaling Chemical May Be Useful in Understanding Parkinson&#8217;s</title>
		<link>http://pharmaexecnews.com/biotechnology/naturally-occurring-brain-signaling-chemical-understanding-parkinsons/</link>
		<comments>http://pharmaexecnews.com/biotechnology/naturally-occurring-brain-signaling-chemical-understanding-parkinsons/#comments</comments>
		<pubDate>Thu, 24 Feb 2011 08:00:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11193</guid>
		<description><![CDATA[Targeting the neuroinflammatory causes of Parkinson&#8217;s disease with a naturally present brain chemical signal could offer a better understanding of the clinical mechanisms of the disease and open a future therapeutic window, reports a team of researchers from the University of South Florida Department Neurosurgery and Brain Repair and the James A. Haley Veterans&#8217; Administration [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/naturally-occurring-brain-signaling-chemical-understanding-parkinsons/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical Industry in India, Top Pharma Companies and Jobs</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/pharmaceutical-industry-india-top-pharma-companies-jobs/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/pharmaceutical-industry-india-top-pharma-companies-jobs/#comments</comments>
		<pubDate>Wed, 23 Feb 2011 14:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11224</guid>
		<description><![CDATA[Pharmaceutical companies in India are growing at a very fast pace and this has made the Indian pharmaceutical industry as the second largest growing industry. Also the pharmaceutical industry in India is the third largest in the world, which will be of US$20 billion by 2015. Mergers and acquisitions are the part of this growth. [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/pharmaceutical-industry-india-top-pharma-companies-jobs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Delivering a Potent Cancer Drug with Nanoparticles can Lessen Side Effects</title>
		<link>http://pharmaexecnews.com/biotechnology/delivering-potent-cancer-drug-nanoparticles-lessen-side-effects/</link>
		<comments>http://pharmaexecnews.com/biotechnology/delivering-potent-cancer-drug-nanoparticles-lessen-side-effects/#comments</comments>
		<pubDate>Wed, 23 Feb 2011 08:00:04 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Nanotechnology]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11189</guid>
		<description><![CDATA[Researchers at MIT and Brigham and Women&#8217;s Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target.  Using the new particles, the researchers were able to [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/delivering-potent-cancer-drug-nanoparticles-lessen-side-effects/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Chimerix Funds Antiviral Drug Work with $45M</title>
		<link>http://pharmaexecnews.com/biotechnology/chimerix-funds-antiviral-drug-work-45m/</link>
		<comments>http://pharmaexecnews.com/biotechnology/chimerix-funds-antiviral-drug-work-45m/#comments</comments>
		<pubDate>Fri, 18 Feb 2011 08:00:15 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11177</guid>
		<description><![CDATA[With two antiviral drug candidates in the clinic, Durham, NC-based Chimerix has raised $45 million in a Series F round of financing. New Leaf Venture Partners led the round. The firm was joined by new investors Pappas Ventures and Morningside Group and existing contributors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/chimerix-funds-antiviral-drug-work-45m/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

